EPISODE · Aug 8, 2019 · 32 MIN
CAR T-cell Explained: Recovering from CAR T-cell Therapy
from The Bloodline with Blood Cancer United Podcast
Rayne H. Rouce, MD On this episode, Alicia and Lizette speak with Dr. Rayne H. Rouce. Dr. Rouce is a pediatric hematologist and oncologist at Texas Children’s Cancer Center where she is a member of the Leukemia and Bone Marrow Transplant programs. She works as part of The Center for Cell and Gene Therapy at Baylor College of Medicine, focused on translating targeted T-cell therapies, and has been involved in every aspect of CAR T-cell development for clinical use. On this episode, Dr. Rouce explains what types of cancers chimeric antigen receptor T-cell therapy, known as CAR T-cell therapy, currently treats, when it may be considered for treatment and why the recovery process may be different for each person. She addresses quality-of-life issues and recommends great questions about CAR T-cell therapy that a patient or caregiver should consider asking their healthcare team. Dr. Rouce shares her excitement for how she sees this therapy improving in the future and continues to work towards discovering how it can be a hopeful option for more and more patients. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: CAR (chimeric antigen receptor) T-cell immunotherapyClinical TrialsPossible Side Effects of CAR T-Cell TherapyClinical TrialsCommunicating with Your Specialist Additional LLS Support Resources: CAR T-Cell Therapy ProcessChimeric Antigen Receptor (CAR) T-Cell Therapy FactsInformation SpecialistsFree telephone/web patient programsFree bookletsFinancial supportCaregiver supportSupport groups Support for this episode provided by Celgene; Kite, A Gilead Company; and Novartis.The post CAR T-cell Explained: Recovering from CAR T-cell Therapy first appeared on The Bloodline with Blood Cancer United Podcast.
NOW PLAYING
CAR T-cell Explained: Recovering from CAR T-cell Therapy
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m